Epidermolysis bullosa (EB) is an inherited, heterogeneous group of rare genetic dermatoses characterized by mucocutaneous fragility and blister formation, inducible by often minimal trauma. A broad phenotypic spectrum has been described, with potentially severe extracutaneous manifestations, morbidity and mortality. Over 30 subtypes are recognized, grouped into four major categories, based predominantly on the plane of cleavage within the skin and reflecting the underlying molecular abnormality: EB simplex, junctional EB, dystrophic EB and Kindler EB. The study of EB has led to seminal advances in our understanding of cutaneous biology. To date, pathogenetic mutations in 16 distinct genes have been implicated in EB, encoding proteins influencing cellular integrity and adhesion. Precise diagnosis is reliant on correlating clinical, electron microscopic and immunohistological features with mutational analyses. In the absence of curative treatment, multidisciplinary care is targeted towards minimizing the risk of blister formation, wound care, symptom relief and specific complications, the most feared of which — and also the leading cause of mortality — is squamous cell carcinoma. Preclinical advances in cell-based, protein replacement and gene therapies are paving the way for clinical successes with gene correction, raising hopes amongst patients and clinicians worldwide.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 16 November 2022
Molecular Diagnosis & Therapy Open Access 17 October 2022
Journal of Medical Case Reports Open Access 07 October 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $79.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fine, J.-D. et al. The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB. J. Am. Acad. Dermatol. 58, 931–950 (2008).
Fine, J.-D. et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J. Am. Acad. Dermatol. 70, 1103–1126 (2014).
Has, C. et al. Consensus re-classification of inherited epidermolysis bullosa and other disorders with skin fragility. Br. J. Dermatol. https://doi.org/10.1111/bjd.18921. (2020). The latest international consensus guidelines for the diagnosis and classification of EB.
Fine, J.-D. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 152, 1231–1238 (2016). The single largest global registry and source of epidemiological data for patients with EB.
Kho, Y. C. et al. Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. Arch. Dermatol. 146, 635–640 (2010).
Fine, J. D. et al. in Epidermolysis bullosa: clinical, epidemiologic, and laboratory advances, and the findings of the National Epidermolysis Bullosa Registry (eds Fine, J. D., Bauer, E. A., McGuire, J., & Moshell, A.). 101–111 (Johns Hopkins University Press, 1999).
Tadini, G. et al. The Italian registry of hereditary epidermolysis bullosa. G. Ital. Dermatol. Venereol. 140, 359–372 (2005).
Pavicic´, Z., Kmet-Vizintin, P., Kansky, A. & Dobric´, I. Occurrence of hereditary bullous epidermolyses in Croatia. Pediatr. Dermatol. 7, 108–110 (1990).
Shinkuma, S., Natsuga, K., Nishie, W. & Shimizu, H. Epidermolysis bullosa in Japan. Dermatol. Clin. 28, 431–432 (2010).
Da˘nescu, S., Has, C., Senila, S., Ungureanu, L. & Cosgarea, R. Epidemiology of inherited epidermolysis bullosa in Romania and genotype–phenotype correlations in patients with dystrophic epidermolysis bullosa. J. Eur. Acad. Dermatol. Venereol. 29, 899–903 (2015).
Horn, H. M., Priestley, G. C., Eady, R. A. & Tidman, M. J. The prevalence of epidermolysis bullosa in Scotland. Br. J. Dermatol. 136, 560–564 (1997).
Yuen, W. Y., Lemmink, H. H., van Dijk-Bos, K. K., Sinke, R. J. & Jonkman, M. F. Herlitz junctional epidermolysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands. Br. J. Dermatol. 165, 1314–1322 (2011).
Vahlquist, A. & Kasia., T. Epidermolysis bullosa care in Scandinavia. Dermatol. Clin. 28, 425–427 (2010).
Castiglia, D. & Zambruno, G. Epidermolysis bullosa care in Italy. Dermatol. Clin. 28, 407–409 (2010).
Hammersen, J. et al. Genotype, clinical course, and therapeutic decision making in 76 infants with severe generalized junctional epidermolysis bullosa. J. Invest. Dermatol. 136, 2150–2157 (2016).
Fuentes, I. et al. Molecular epidemiology of junctional epidermolysis bullosa: discovery of novel and frequent LAMB3 mutations in Chilean patients with diagnostic significance. Br. J. Dermatol. 176, 1090–1092 (2017).
Abu, Sa’d,J. et al. Molecular epidemiology of hereditary epidermolysis bullosa in a Middle Eastern population. J. Invest. Dermatol. 126, 777–781 (2006).
Abahussein, A. A., al-Zayir, A. A., Mostafa, W. Z. & Okoro, A. N. Epidermolysis bullosa in the eastern province of Saudi Arabia. Int. J. Dermatol. 32, 579–581 (1993).
Fine, J.-D., Johnson, L. B., Weiner, M., Li, K.-P. & Suchindran, C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006. J. Am. Acad. Dermatol. 60, 203–211 (2009).
Fine, J. D. & Lanschuetzer, C. M. in Life with Epidermolysis Bullosa (EB) (eds Fine, J. D. & Hintner H.) 116–131 (SpringerWein, 2009).
Cancer Research UK. Melanoma skin cancer incidence statistics. CRUK http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/skin-cancer/incidence#heading-Eleven (2019).
Kim, M. et al. Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand. Acta Derm. Venereol. 98, 70–76 (2018).
Fine, J.-D., Johnson, L. B., Weiner, M. & Suchindran, C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J. Pediatr. 152, 276–280 (2008).
Yuen, W. Y. et al. Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa. Br. J. Dermatol. 167, 374–382 (2012).
Fine, J. D., Hall, M., Weiner, M., Li, K. P. & Suchindran, C. The risk of cardiomyopathy in inherited epidermolysis bullosa. Br. J. Dermatol. 159, 677–682 (2008).
Fine, J.-D. et al. Inherited epidermolysis bullosa and the risk of death from renal disease: experience of the National Epidermolysis Bullosa Registry. Am. J. Kidney Dis. 44, 651–660 (2004).
Fine, J.-D. et al. Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry. Am. J. Ophthalmol. 138, 254–262 (2004).
J. E., L.-C. et al. Kindler syndrome: a focal adhesion genodermatosis. Br. J. Dermatol. 160, 233–242 (2009).
Guerrero-Aspizua, S. et al. Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients. Orphanet J. Rare Dis. 14, 183 (2019).
Mizutani, H. et al. Cutaneous and laryngeal squamous cell carcinoma in mixed epidermolysis bullosa, kindler syndrome. Case Rep. Dermatol. 4, 133–138 (2012).
Lane, E. B. et al. A mutation in the conserved helix termination peptide of keratin 5 in hereditary skin blistering. Nature 356, 244–246 (1992).
Homberg, M. & Magin, T. M. Beyond expectations: novel insights into epidermal keratin function and regulation. Int. Rev. Cell Mol. Biol. 311, 265–306 (2014).
Coulombe, P. A. & Lee, C.-H. Defining keratin protein function in skin epithelia: epidermolysis bullosa simplex and its aftermath. J. Invest. Dermatol. 132, 763–775 (2012). A review article describing the function of keratin intermediate filaments in basal epidermal keratinocytes.
Bruckner-Tuderman, L. & Has, C. Disorders of the cutaneous basement membrane zone — the paradigm of epidermolysis bullosa. Matrix Biol. 33, 29–34 (2014).
Castañón, M. J., Walko, G., Winter, L. & Wiche, G. Plectin-intermediate filament partnership in skin, skeletal muscle, and peripheral nerve. Histochem. Cell Biol. 140, 33–53 (2013).
Bolling, M. C. et al. Plectin mutations underlie epidermolysis bullosa simplex in 8% of patients. J. Invest. Dermatol. 134, 273–276 (2014).
Natsuga, K. et al. Plectin deficiency leads to both muscular dystrophy and pyloric atresia in epidermolysis bullosa simplex. Hum. Mutat. 31, E1687–E1698 (2010).
He, Y. et al. Monoallelic mutations in the translation initiation codon of KLHL24 cause skin fragility. Am. J. Hum. Genet. 99, 1395–1404 (2016).
Lin, Z. et al. Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility. Nat. Genet. 48, 1508–1516 (2016).
Lee, J. Y. W. et al. Mutations in KLHL24 add to the molecular heterogeneity of epidermolysis bullosa simplex. J. Invest. Dermatol. 137, 1378–1380 (2017). This paper describes KLHL24 mutations in EB simplex.
Herrmann, H. & Aebi, U. Intermediate filaments: structure and assembly. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a018242 (2016).
Coulombe, P. A., Kerns, M. L. & Fuchs, E. Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J. Clin. Invest. 119, 1784–1793 (2009).
Fine, J.-D. Inherited epidermolysis bullosa. Orphanet J. Rare Dis. 5, 12 (2010).
Bohnekamp, J. et al. A drosophila model of epidermolysis bullosa simplex. J. invest. Dermatol. 135, 2031–2039 (2015).
Löffek, S. et al. The ubiquitin ligase CHIP/STUB1 targets mutant keratins for degradation. Hum. Mutat. 31, 466–476 (2010).
Ramms, L. et al. Keratins as the main component for the mechanical integrity of keratinocytes. Proc. Natl Acad. Sci. USA 110, 18513–18518 (2013).
Homberg, M. et al. Distinct impact of two keratin mutations causing epidermolysis bullosa simplex on keratinocyte adhesion and stiffness. J. Investig. Dermatol. 135, 2437–2445 (2015).
Beriault, D. R. et al. The mechanical behavior of mutant K14-R125P keratin bundles and networks in NEB-1 keratinocytes. PLoS ONE 7, e31320 (2012).
Seltmann, K., Cheng, F., Wiche, G., Eriksson, J. E. & Magin, T. M. Keratins stabilize hemidesmosomes through regulation of β4-integrin turnover. J. Invest. Dermatol. 135, 1609–1620 (2015).
McGrath, J. A. et al. Germline mutation in EXPH5 implicates the Rab27B effector protein slac20b in inherited skin fragility. Am. J. Hum. Genet. 91, 1115–1121 (2012).
Sawant, M. et al. Threonine 150 phosphorylation of keratin 5 is linked to epidermolysis bullosa simplex and regulates filament assembly and cell viability. J. Invest. Dermatol. 138, 627–636 (2018).
Morley, S. M. et al. Temperature sensitivity of the keratin cytoskeleton and delayed spreading of keratinocyte lines derived from EBS patients. J. Cell Sci. 108, 3463–3471 (1995). This paper demonstrates thermolability of the keratin cytoskeleton, which manifests clinically as increased blistering and skin fragility in warm conditions.
Lu, H. et al. Induction of inflammatory cytokines by a keratin mutation and their repression by a small molecule in a mouse model for EBS. J. Invest. Dermatol. 127, 2781–2789 (2007).
Castela, E. et al. Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment. Br. J. Dermatol. 180, 357–364 (2019).
Yoneda, K. et al. An autocrine/paracrine loop linking keratin 14 aggregates to tumor necrosis factor alpha-mediated cytotoxicity in a keratinocyte model of epidermolysis bullosa simplex. J. Biol. Chem. 279, 7296–7303 (2004).
Roth, W., Reuter, U., Wohlenberg, C., Bruckner-Tuderman, L. & Magin, T. M. Cytokines as genetic modifiers in K5–/– mice and in human epidermolysis bullosa simplex. Hum. Mutat. 30, 832–841 (2009).
Castiglia, D. et al. T-lymphocytes are directly involved in the clinical expression of migratory circinate erythema in epidermolysis bullosa simplex patients. Acta Derm. Venereol. 94, 307–311 (2014).
Jariwala, S. P., Abrams, E., Benson, A., Fodeman, J. & Zheng, T. The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis. Clin. Exp. Allergy 41, 1515–1520 (2011).
Kumar, V. et al. Keratin-dependent thymic stromal lymphopoietin expression suggests a link between skin blistering and atopic disease. J. Allergy Clin. Immunol. 138, 1461–1464.e6 (2016).
Kana, Y. et al. Keratotic lesions in epidermolysis bullosa simplex with mottled pigmentation. J. Am. Acad. Dermatol. 52, 172–173 (2005).
Pan, B. et al. Peripheral neuropathic changes in pachyonychia congenita. Pain 157, 2843–2853 (2016).
Kroeger, J. K., Hofmann, S. C., Leppert, J., Has, C. & Franzke, C.-W. Amino acid duplication in the coiled-coil structure of collagen XVII alters its maturation and trimerization causing mild junctional epidermolysis bullosa. Hum. Mol. Genet. 26, 479–488 (2017).
Pasmooij, A. M. G., Pas, H. H., Deviaene, F. C. L., Nijenhuis, M. & Jonkman, M. F. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am. J. Hum. Genet. 77, 727–740 (2005). Revertant mosaicism (‘natural gene therapy’) in junctional EB is a phenomenon with the potential to be harnessed as a therapeutic strategy, as described in this paper.
Nakano, A. et al. Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. Hum. Genet. 110, 41–51 (2002).
Posteraro, P. et al. Laminin-5 mutational analysis in an Italian cohort of patients with junctional epidermolysis bullosa. J. Invest. Dermatol. 123, 639–648 (2004).
Wright, J. T., Carrion, I. A. & Morris, C. The molecular basis of hereditary enamel defects in humans. J. Dent. Res. 94, 52–61 (2015).
Tanimura, S. et al. Hair follicle stem cells provide a functional niche for melanocyte stem cells. Cell Stem Cell 8, 177–187 (2011).
Watanabe, M. et al. Type XVII collagen coordinates proliferation in the interfollicular epidermis. eLife https://doi.org/10.7554/eLife.26635 (2017).
Matsumura, H. et al. Hair follicle aging is driven by transepidermal elimination of stem cells via COL17A1 proteolysis. Science 351, aad4395 (2016).
Franzke, C.-W., Bruckner-Tuderman, L. & Blobel, C. P. Shedding of collagen XVII/BP180 in skin depends on both ADAM10 and ADAM9. J. Biol. Chem. 284, 23386–23396 (2009).
Nishie, W., Kiritsi, D., Nyström, A., Hofmann, S. C. & Bruckner-Tuderman, L. Dynamic interactions of epidermal collagen XVII with the extracellular matrix: laminin 332 as a major binding partner. Am. J. Pathol. 179, 829–837 (2011).
Nishie, W., Jackow, J., Hofmann, S. C., Franzke, C.-W. & Bruckner-Tuderman, L. Coiled coils ensure the physiological ectodomain shedding of collagen XVII. J. Biol. Chem. 287, 29940–29948 (2012).
Jacków, J., Löffek, S., Nyström, A., Bruckner-Tuderman, L. & Franzke, C.-W. Collagen XVII shedding suppresses re-epithelialization by directing keratinocyte migration and dampening mTOR signaling. J. Invest. Dermatol. 136, 1031–1041 (2016).
Nishie, W. et al. Context-dependent regulation of collagen XVII ectodomain shedding in skin. Am. J. Pathol. 185, 1361–1371 (2015).
Galiger, C. et al. Targeting of cell surface proteolysis of collagen XVII impedes squamous cell carcinoma progression. Mol. Ther. 26, 17–30 (2018).
Has, C. & Nyström, A. Epidermal basement membrane in health and disease. Curr. Top. Membr. 76, 117–170 (2015).
Reimer, A. et al. Natural history and clinical outcome of junctional epidermolysis bullosa generalized intermediate due to a LAMA3 mutation. Br. J. Dermatol. 178, 973–975 (2018).
Hirsch, T. et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 551, 327–332 (2017). A case of successfully applied ex vivo gene therapy in a 7-year-old boy with laminin 332-deficient junctional EB via treatment with virally integrated transgenic autologous epidermal grafts.
Borradori, L. & Sonnenberg, A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J. Invest. Dermatol. 112, 411–418 (1999).
Viquez, O. M. et al. Integrin alpha6 maintains the structural integrity of the kidney collecting system. Matrix Biol. 57–58, 244–257 (2017).
De Arcangelis, A. et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut 66, 1748–1760 (2017).
Has, C. et al. Integrin α3 mutations with kidney, lung, and skin disease. N. Engl. J. Med. 366, 1508–1514 (2012).
Has, C. & He, Y. Renal-skin syndromes. Cell Tissue Res. 369, 63–73 (2017).
Borza, C. M., Chen, X., Zent, R. & Pozzi, A. Cell receptor-basement membrane interactions in health and disease: a kidney-centric view. Curr. Top. Membr. 76, 231–253 (2015).
Pozzi, A. & Zent, R. Integrins in kidney disease. J. Am. Soc. Nephrol. 24, 1034–1039 (2013).
Nicolaou, N. et al. Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome. J. Clin. Invest. 122, 4375–4387 (2012).
Yalcin, E. G. et al. Crucial role of posttranslational modifications of integrin α3 in interstitial lung disease and nephrotic syndrome. Hum. Mol. Genet. 24, 3679–3688 (2015).
Yamada, M. & Sekiguchi, K. Disease-associated single amino acid mutation in the calf-1 domain of integrin α3 leads to defects in its processing and cell surface expression. Biochem. Biophys. Res. Commun. 441, 988–993 (2013).
Lunstrum, G. P., Sakai, L. Y., Keene, D. R., Morris, N. P. & Burgeson, R. E. Large complex globular domains of type VII procollagen contribute to the structure of anchoring fibrils. J. Biol. Chem. 261, 9042–9048 (1986).
Sakai, L. Y., Keene, D. R., Morris, N. P. & Burgeson, R. E. Type VII collagen is a major structural component of anchoring fibrils. J. Cell Biol. 103, 1577–1586 (1986).
Keene, D. R. et al. Collagen forms an extended network of anchoring fibrils. J. Cell Biol. 104, 611–621 (1987).
Lunstrum, G. P. et al. Anchoring fibrils contain the carboxyl-terminal globular domain of type VII procollagen, but lack the amino-terminal globular domain. J. Biol. Chem. 262, 13706–13712 (1987).
Palade, G. E. & Farquhar, M. G. A special fibril of the dermis. J. Cell Biol. 27, 215–224 (1965).
Tidman, M. J. & Eady, R. A. Evaluation of anchoring fibrils and other components of the dermal–epidermal junction in dystrophic epidermolysis bullosa by a quantitative ultrastructural technique. J. Invest. Dermatol. 84, 374–377 (1985).
Nyström, A. et al. Collagen VII plays a dual role in wound healing. J. Clin. Invest. 123, 3498–3509 (2013).
Bauer, E. A. & Tabas, M. A perspective on the role of collagenase in recessive dystrophic epidermolysis bullosa. Arch. Dermatol. 124, 734–736 (1988).
Bruckner-Tuderman, L., Höpfner, B. & Hammami-Hauasli, N. Biology of anchoring fibrils: lessons from dystrophic epidermolysis bullosa. Matrix Biol. 18, 43–54 (1999).
Cui, Y., Hagan, K. W., Zhang, S. & Peltz, S. Identification and characterization of genes that are required for the accelerated degradation of mRNAs containing a premature translational termination codon. Genes Dev. 9, 423–436 (1995).
Christiano, A. M., Anhalt, G., Gibbons, S., Bauer, E. A. & Uitto, J. Premature termination codons in the type VII collagen gene (COL7A1) underlie severe, mutilating recessive dystrophic epidermolysis bullosa. Genomics 21, 160–168 (1994).
Has, C., Nyström, A., Saeidian, A. H., Bruckner-Tuderman, L. & Uitto, J. Epidermolysis bullosa: molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol. 71–72, 313–329 (2018).
Sakuntabhai, A. et al. Deletions within COL7A1 exons distant from consensus splice sites alter splicing and produce shortened polypeptides in dominant dystrophic epidermolysis bullosa. Am. J. Hum. Genet. 63, 737–748 (1998).
Hammami-Hauasli, N. et al. Some, but not all, glycine substitution mutations in COL7A1 result in intracellular accumulation of collagen VII, loss of anchoring fibrils, and skin blistering. J. Biol. Chem. 273, 19228–19234 (1998).
Hatta, N., Takata, M. & Shimizu, H. Spontaneous disappearance of intraepidermal type VII collagen in a patient with dystrophic epidermolysis bullosa. Br. J. Dermatol. 133, 619–624 (1995).
Has, C. et al. Kindler syndrome: extension of FERMT1 mutational spectrum and natural history. Hum. Mutat. 32, 1204–1212 (2011).
Jobard, F. et al. Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome. Hum. Mol. Genet. 12, 925–935 (2003). This paper describes the initial identification of FERMT1 in Kindler EB.
Siegel, D. H. et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am. J. Hum. Genet. 73, 174–187 (2003).
Rognoni, E., Ruppert, R. & Fässler, R. The kindlin family: functions, signaling properties and implications for human disease. J. Cell Sci. 129, 17–27 (2016).
Heinemann, A. et al. Induction of phenotype modifying cytokines by FERMT1 mutations. Hum. Mutat. 32, 397–406 (2011).
Qu, H., Wen, T., Pesch, M. & Aumailley, M. Partial loss of epithelial phenotype in kindlin-1-deficient keratinocytes. Am. J. Pathol. 180, 1581–1592 (2012).
Rognoni, E. et al. Kindlin-1 controls Wnt and TGF-β availability to regulate cutaneous stem cell proliferation. Nat. Med. 20, 350–359 (2014).
Maier, K. et al. UV-B-induced cutaneous inflammation and prospects for antioxidant treatment in Kindler syndrome. Hum. Mol. Genet. 25, 5339–5352 (2016).
Fuentes, I. et al. Reduced microbial diversity is a feature of recessive dystrophic epidermolysis bullosa-involved skin and wounds. J. Invest. Dermatol. 138, 2492–2495 (2018).
Atanasova, V. S. et al. Thrombospondin-1 is a major activator of TGF-beta signaling in recessive dystrophic epidermolysis bullosa fibroblasts. J. Invest. Dermatol. 139, 1497–1505.e5 (2019).
Cianfarani, F., Zambruno, G., Castiglia, D. & Odorisio, T. Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa. Am. J. Pathol. 187, 1445–1453 (2017).
Guerra, L., Odorisio, T., Zambruno, G. & Castiglia, D. Stromal microenvironment in type VII collagen-deficient skin: the ground for squamous cell carcinoma development. Matrix Biol. 63, 1–10 (2017).
Reed, W. B. et al. Epidermolysis bullosa dystrophica with epidermal neoplasms. Arch. Dermatol. 110, 894–902 (1974).
Watt, S. A. et al. Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene 30, 4666–4677 (2011).
Ng, Y.-Z. et al. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Cancer Res. 72, 3522–3534 (2012).
Cho, R. J. et al. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci. Transl Med. 10, eaas9668 (2018).
Thannickal, V. J. et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278, 12384–12389 (2003).
Khan, Z. & Marshall, J. F. The role of integrins in TGFβ activation in the tumour stroma. Cell Tissue Res. 365, 657–673 (2016).
Martins, V. L. et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J. Cell Sci. 122, 1788–1799 (2009).
Fritsch, A. et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J. Clin. Invest. 118, 1669–1679 (2008).
Küttner, V. et al. Global remodelling of cellular microenvironment due to loss of collagen VII. Mol. Syst. Biol. 9, 657 (2013).
Martins, V. L. et al. Suppression of TGFβ and angiogenesis by type VII collagen in cutaneous SCC. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djv293 (2016).
Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199–210 (2008).
Kendall, R. T. & Feghali-Bostwick, C. A. Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol. 5, 123 (2014).
Samuel, M. S. et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 19, 776–791 (2011).
Mittapalli, V. R. et al. Injury-driven stiffening of the dermis expedites skin carcinoma progression. Cancer Res. 76, 940–951 (2016).
Hoste, E. et al. Innate sensing of microbial products promotes wound-induced skin cancer. Nat. Commun. 6, 5932 (2015).
Has, C. et al. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. Br. J. Dermatol. 182, 574–592 (2020). Recent expert guidance for the laboratory diagnosis of EB.
Has, C. & He, Y. Research techniques made simple: immunofluorescence antigen mapping in epidermolysis bullosa. J. Invest. Dermatol. 136, e65–e71 (2016). The application of monoclonal antibodies to dermal–epidermal junction proteins to determine the site of pathology in EB.
Intong, L. R. A. & Murrell, D. F. How to take skin biopsies for epidermolysis bullosa. Dermatol. Clin. 28, 197–200 (2010).
Hintner, H. et al. Immunofluorescence mapping of antigenic determinants within the dermal–epidermal junction in the mechanobullous diseases. J. Invest. Dermatol. 76, 113–118 (1981).
Heagerty, A. H., Kennedy, A. R., Leigh, I. M., Purkis, P. & Eady, R. A. Identification of an epidermal basement membrane defect in recessive forms of dystrophic epidermolysis bullosa by LH 7:2 monoclonal antibody: use in diagnosis. Br. J. Dermatol. 115, 125–131 (1986).
Heagerty, A. H. et al. GB3 monoclonal antibody for diagnosis of junctional epidermolysis bullosa. Lancet 1, 860 (1986).
Yiasemides, E., Walton, J., Marr, P., Villanueva, E. V. & Murrell, D. F. A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. Am. J. Dermatopathol. 28, 387–394 (2006).
Petronius, D., Bergman, R., Ben Izhak, O., Leiba, R. & Sprecher, E. A comparative study of immunohistochemistry and electron microscopy used in the diagnosis of epidermolysis bullosa. Am. J. Dermatopathol. 25, 198–203 (2003).
Hiremagalore, R., Kubba, A., Bansel, S. & Jerajani, H. Immunofluorescence mapping in inherited epidermolysis bullosa: a study of 86 cases from India. Br. J. Dermatol. 172, 384–391 (2015).
Takeichi, T. et al. Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory. Br. J. Dermatol. 172, 94–100 (2015). This article highlights the evolving landscape for mutational testing in EB.
Tenedini, E. et al. Amplicon-based next-generation sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa. Br. J. Dermatol. 173, 731–738 (2015).
Christiano, A. M., Pulkkinen, L., McGrath, J. A. & Uitto, J. Mutation-based prenatal diagnosis of Herlitz junctional epidermolysis bullosa. Prenat. Diagn. 17, 343–354 (1997).
Vahidnezhad, H. et al. Multigene next-generation sequencing panel identifies pathogenic variants in patients with unknown subtype of epidermolysis bullosa: subclassification with prognostic implications. J. Invest. Dermatol. 137, 2649–2652 (2017).
Vahidnezhad, H. et al. Dystrophic epidermolysis bullosa: COL7A1 mutation landscape in a multi-ethnic cohort of 152 extended families with high degree of customary consanguineous marriages. J. Invest. Dermatol. 137, 660–669 (2017).
Nagai, M. et al. Localised dominant dystrophic epidermolysis bullosa with a novel de novo mutation in COL7A1 diagnosed by next-generation sequencing. Acta Derm. Venereol. 95, 629–631 (2015).
Bauer, J. A. in Life with Epidermolysis Bullosa: Etiology, Diagnosis, and Multidisciplinary Care and Therapy (eds Fine, J. D. & Hintner, H.) 89–95 (Springer Verlag, 2009).
Christiano, A. M. et al. Prenatal diagnosis for recessive dystrophic epidermolysis bullosa in 10 families by mutation and haplotype analysis in the type VII collagen gene (COL7A1). Mol. Med. 2, 59–76 (1996).
Has, C. et al. Monoallelic large intragenic KRT5 deletions account for genetically unsolved cases of epidermolysis bullosa simplex. J. Invest. Dermatol. 137, 2231–2234 (2017).
Rehm, H. L. et al. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15, 733–747 (2013).
Eady, R. A., Gunner, D. B., Tidman, M. J., Nicolaides, K. H. & Rodeck, C. H. Rapid processing of fetal skin for prenatal diagnosis by light and electron microscopy. J. Clin. Pathol. 37, 633–638 (1984).
Heagerty, A. H., Kennedy, A. R., Gunner, D. B. & Eady, R. A. Rapid prenatal diagnosis and exclusion of epidermolysis bullosa using novel antibody probes. J. Invest. Dermatol. 86, 603–605 (1986).
Heagerty, A. H. et al. Rapid prenatal diagnosis of epidermolysis bullosa letalis using GB3 monoclonal antibody. Br. J. Dermatol. 117, 271–275 (1987).
Fassihi, H. et al. Prenatal diagnosis for severe inherited skin disorders: 25 years’ experience. Br. J. Dermatol. 154, 106–113 (2006).
Fassihi, H., Renwick, P. J., Black, C. & McGrath, J. A. Single cell PCR amplification of microsatellites flanking the COL7A1 gene and suitability for preimplantation genetic diagnosis of Hallopeau–Siemens recessive dystrophic epidermolysis bullosa. J. Dermatol. Sci. 42, 241–248 (2006).
Fassihi, H. et al. Preimplantation genetic diagnosis of skin fragility-ectodermal dysplasia syndrome. Br. J. Dermatol. 154, 546–550 (2006).
Fine, J.-D. & Mellerio, J. E. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J. Am. Acad. Dermatol. 61, 367–386 (2009).
Fine, J.-D. & Mellerio, J. E. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J. Am. Acad. Dermatol. 61, 387–404 (2009).
Denyer, J. Management of severe blistering disorders. Semin. Neonatol. 5, 321–324 (2000).
Denyer, J., Pillay, E. & Clapham, J. Best practice guidelines for skin and wound care in epidermolysis bullosa. An International Consensus. Wounds International https://www.woundsinternational.com/download/resource/5921 (2017). Best practice guidelines for wound management in EB.
Singer, H. M. et al. Wound culture isolated antibiograms and caregiver-reported skin care practices in children with epidermolysis bullosa. Pediatr. Dermatol. 35, 92–96 (2018).
Mellerio, J. E. et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br. J. Dermatol. 174, 56–67 (2016). Best practice guidelines for management of squamous cell carcinoma arising in EB.
Piccerillo, A., El Hachem, M., De Vito, R., De Luca, E. V. & Peris, K. Pembrolizumab for treatment of a patient with multiple cutaneous squamous cell carcinomas and recessive dystrophic epidermolysis bullosa. JAMA Dermatol. 156, 708–710 (2020).
Atanasova, V. S. et al. Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. Clin. Cancer Res. 25, 3384–3391 (2019).
Fine, J.-D., Johnson, L. B., Weiner, M. & Suchindran, C. Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the National Epidermolysis Bullosa Registry. J. Pediatr. Gastroenterol. Nutr. 46, 147–158 (2008).
Freeman, E. B. et al. Gastrointestinal complications of epidermolysis bullosa in children. Br. J. Dermatol. 158, 1308–1314 (2008).
Montaudié, H., Chiaverini, C., Sbidian, E., Charlesworth, A. & Lacour, J. P. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases. Orphanet J. Rare Dis. 11, 117 (2016).
Azizkhan, R. G. et al. Esophageal strictures in children with recessive dystrophic epidermolysis bullosa: an 11-year experience with fluoroscopically guided balloon dilatation. J. Pediatr. Surg. 41, 55–60 (2006).
Haynes, L. Nutrition for children with epidermolysis bullosa. Dermatol. Clin. 28, 289–301 (2010).
Haynes, L., Mellerio, J. E. & Martinez, A. E. Gastrostomy tube feeding in children with epidermolysis bullosa: consideration of key issues. Pediatr. Dermatol. 29, 277–284 (2012).
Hubbard, L., Haynes, L., Sklar, M., Martinez, A. E. & Mellerio, J. E. The challenges of meeting nutritional requirements in children and adults with epidermolysis bullosa: proceedings of a multidisciplinary team study day. Clin. Exp. Dermatol. 36, 579–584 (2011).
Hwang, S. J. E., Daniel, B. S., Fergie, B., Davey, J. & Murrell, D. F. Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. Int. J. Womens Dermatol. 1, 37–40 (2015).
Kuo, D. J., Bruckner, A. L. & Jeng, M. R. Darbepoetin alfa and ferric gluconate ameliorate the anemia associated with recessive dystrophic epidermolysis bullosa. Pediatr. Dermatol. 23, 580–585 (2006).
Fewtrell, M. S. et al. Bone mineralization in children with epidermolysis bullosa. Br. J. Dermatol. 154, 959–962 (2006).
Bruckner, A. L. et al. Correlates of low bone mass in children with generalized forms of epidermolysis bullosa. J. Am. Acad. Dermatol. 65, 1001–1009 (2011).
Martinez, A. E. & Mellerio, J. E. Osteopenia and osteoporosis in epidermolysis bullosa. Dermatol. Clin. 28, 353–355 (2010).
Fine, J. D. et al. Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry, 1986–2002. J. Hand Surg. Br. 30, 14–22 (2005).
Bernardis, C. & Box, R. Surgery of the hand in recessive dystrophic epidermolysis bullosa. Dermatol. Clin. 28, 335–341 (2010).
Khan, M. T. et al. Foot care in epidermolysis bullosa: evidence-based guideline. Br. J. Dermatol. https://doi.org/10.1111/bjd.18381 (2019). Best practice podiatry guidelines in EB.
Bolling, M. C. et al. PLEC1 mutations underlie adult-onset dilated cardiomyopathy in epidermolysis bullosa simplex with muscular dystrophy. J. Invest. Dermatol. 130, 1178–1181 (2010).
Fine, J.-D., Johnson, L. B., Weiner, M. & Suchindran, C. Tracheolaryngeal complications of inherited epidermolysis bullosa: cumulative experience of the national epidermolysis bullosa registry. Laryngoscope. 117, 1652–1660 (2007).
Hore, I. et al. The management of general and disease specific ENT problems in children with epidermolysis bullosa — a retrospective case note review. Int. J. Pediatr. Otorhinolaryngol. 71, 385–391 (2007).
Fine, J.-D. et al. Genitourinary complications of inherited epidermolysis bullosa: experience of the National Epidermylosis Bullosa Registry and review of the literature. J. Urol. 172, 2040–2044 (2004).
Chan, S. M. H., Dillon, M. J., Duffy, P. G. & Atherton, D. J. Nephro-urological complications of epidermolysis bullosa in paediatric patients. Br. J. Dermatol. 156, 143–147 (2007).
Iida, H. et al. Successfully maintained hemodialysis for the treatment of chronic renal failure in a patient with Hallopeau–Siemens type recessive dystrophic epidermolysis bullosa. J. Dermatol. 39, 1088–1089 (2012).
Ahmadi, J. & Antaya, R. Successful peritoneal dialysis in a patient with recessive dystrophic epidermolysis bullosa. Pediatr. Dermatol. 24, 589–590 (2007).
Ungureanu, S., Adni, T., Brown, T., Inston, N. & Heagerty, A. Successful renal transplant in a patient with non-Herlitz junctional epidermolysis bullosa. Clin. Exp. Dermatol. 39, 330–332 (2014).
Schwieger-Briel, A. et al. Epidermolysis bullosa simplex with KLHL24 mutations is associated with dilated cardiomyopathy. J. Invest. Dermatol. 139, 244–249 (2019).
Ryan, T. D. et al. Ventricular dysfunction and aortic dilation in patients with recessive dystrophic epidermolysis bullosa. Br. J. Dermatol. 174, 671–673 (2016).
Davila-Seijo, P. et al. Prioritization of therapy uncertainties in dystrophic epidermolysis bullosa: where should research direct to? An example of priority setting partnership in very rare disorders. Orphanet J. Rare Dis. 8, 61 (2013).
von Bischhoffshausen, S. et al. Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy. Brain 140, 1238–1251 (2017).
Goldschneider, K. R. et al. Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med. 12, 178 (2014).
Schräder, N. H. B., Duipmans, J. C., Molenbuur, B., Wolff, A. P. & Jonkman, M. F. Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. Br. J. Dermatol. 180, 922–924 (2019).
Martin, K. et al. Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines. Orphanet J. Rare Dis. 14, 133 (2019). Best practice guidelines for psychosocial assessment and support in EB.
Danial, C. et al. Evaluation of treatments for pruritus in epidermolysis bullosa. Pediatr. Dermatol. 32, 628–634 (2015).
Shehadeh, W., Sarig, O., Bar, J., Sprecher, E. & Samuelov, L. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br. J. Dermatol. https://doi.org/10.1111/bjd.18855 (2020).
Peking, P., Koller, U. & Murauer, E. M. Functional therapies for cutaneous wound repair in epidermolysis bullosa. Adv. Drug. Deliv. Rev. 129, 330–343 (2018).
Rashidghamat, E. & McGrath, J. A. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis. Res. 6, 6–20 (2017).
Wong, T. et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 128, 2179–2189 (2008).
Petrof, G., Martinez-Queipo, M., Mellerio, J. E., Kemp, P. & McGrath, J. A. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br. J. Dermatol. 169, 1025–1033 (2013).
Lwin, S. M. et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight https://doi.org/10.1172/jci.insight.126243 (2019).
Conget, P. et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 12, 429–431 (2010).
Petrof, G. et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 135, 2319–2321 (2015).
Rashidghamat, E. et al. Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J. Am. Acad. Dermatol. https://doi.org/10.1016/j.jaad.2019.11.038 (2020).
Wagner, J. E. et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med. 363, 629–639 (2010).
Ebens, C. L. et al. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts. Br. J. Dermatol. 181, 1238–1246 (2019).
Mavilio, F. et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12, 1397–1402 (2006).
Eichstadt, S. et al. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight https://doi.org/10.1172/jci.insight.130554 (2019).
Siprashvili, Z. et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA 316, 1808–1817 (2016).
Pasmooij, A. M. G., Jonkman, M. F. & Uitto, J. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy. Discov. Med. 14, 167–179 (2012).
Kiritsi, D. et al. Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa. J. Invest. Dermatol. 134, 2097–2104 (2014).
Gostyn´ski, A., Pasmooij, A. M. G. & Jonkman, M. F. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa. J. Am. Acad. Dermatol. 70, 98–101 (2014).
Matsumura, W. et al. Cultured epidermal autografts from clinically revertant skin as a potential wound treatment for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 139, 2115–2124.e11 (2019).
March, O. P., Kocher, T. & Koller, U. Context-dependent strategies for enhanced genome editing of genodermatoses. Cells https://doi.org/10.3390/cells9010112 (2020).
Shinkuma, S., Guo, Z. & Christiano, A. M. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Proc. Natl Acad. Sci. USA 113, 5676–5681 (2016).
Kocher, T. et al. Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases. Mol. Ther. 25, 2585–2598 (2017).
Webber, B. R. et al. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen. Med. https://doi.org/10.1038/npjregenmed.2016.14 (2016).
Jacków, J. et al. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells. Proc. Natl Acad. Sci. USA 116, 26846–26852 (2019).
Bonafont, J. et al. Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing. Mol. Ther. 27, 986–998 (2019).
Osborn, M. J. et al. Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. J. Invest. Dermatol. 140, 338–347.e5 (2020).
Zhou, D. et al. Highly branched poly(β-amino ester)s for skin gene therapy. J. Control. Release 244, 336–346 (2016).
Liemberger, B. et al. RNA trans-splicing modulation via antisense molecule interference. Int. J. Mol. Sci. https://doi.org/10.3390/ijms19030762 (2018).
Hou, Y. et al. Intravenously administered recombinant human type VII collagen derived from Chinese hamster ovary cells reverses the disease phenotype in recessive dystrophic epidermolysis bullosa mice. J. Invest. Dermatol. 135, 3060–3067 (2015).
Woodley, D. T. et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J. Clin. Invest. 127, 3028–3038 (2017). This paper describes the administration of topical or intradermal gentamicin-induced type VII collagen and anchoring fibril formation via suppression of nonsense mutations in recessive dystrophic EB.
Atanasova, V. S. et al. Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 137, 1842–1849 (2017).
Moss, C., Wong, A. & Davies, P. The Birmingham epidermolysis bullosa severity score: development and validation. Br. J. Dermatol. 160, 1057–1065 (2009).
Loh, C. C. H. et al. Development, reliability, and validity of a novel epidermolysis bullosa disease activity and scarring index (EBDASI). J. Am. Acad. Dermatol. 70, 89–97.e13 (2014).
Bruckner, A. L. et al. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB). Br. J. Dermatol. 178, 1128–1134 (2018).
Horn, H. M. & Tidman, M. J. Quality of life in epidermolysis bullosa. Clin. Exp. Dermatol. 27, 707–710 (2002).
Frew, J. W., Martin, L. K., Nijsten, T. & Murrell, D. F. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br. J. Dermatol. 161, 1323–1330 (2009).
Jeon, I. K., On, H. R. & Kim, S.-C. Quality of life and economic burden in recessive dystrophic epidermolysis bullosa. Ann. Dermatol. 28, 6–14 (2016).
van Scheppingen, C., Lettinga, A. T., Duipmans, J. C., Maathuis, C. G. B. & Jonkman, M. F. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm. Venereol. 88, 143–150 (2008).
van Scheppingen, C., Lettinga, A. T., Duipmans, J. C., Maathuis, K. G. B. & Jonkman, M. F. The main problems of parents of a child with epidermolysis bullosa. Qual. Health Res. 18, 545–556 (2008).
Adni, T., Martin, K. & Mudge, E. The psychosocial impact of chronic wounds on patients with severe epidermolysis bullosa. J. Wound Care 21, 530–536 (2012).
Fine, J. D., Johnson, L. B., Weiner, M. & Suchindran, C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin. Exp. Dermatol. 29, 122–127 (2004).
Brun, J. et al. Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex. Orphanet J. Rare Dis. 12, 119 (2017).
Fortuna, G., Aria, M., Cepeda-Valdes, R., Moreno Trevino, M. G. & Salas-Alanís, J. C. Pain in patients with dystrophic epidermolysis bullosa: association with anxiety and depression. Psychiatry Investig. 14, 746–753 (2017).
Schräder, N. H. B., Yuen, W. Y. & Jonkman, M. F. Pain quality assessment scale for epidermolysis bullosa. Acta Derm. Venereol. 98, 346–349 (2018).
Snauwaert, J. J. L. et al. Burden of itch in epidermolysis bullosa. Br. J. Dermatol. 171, 73–78 (2014).
Davila-Seijo, P., Hernández-Martín, Á., Morcillo-Makow, E., Rajan, C. & García-Doval, I. Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians. J. Am. Acad. Dermatol. 71, 1008–1011 (2014).
Natsuga, K., Shinkuma, S., Nishie, W. & Shimizu, H. Animal models of epidermolysis bullosa. Dermatol. Clin. 28, 137–142 (2010).
Wenzel, D. et al. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa. Sci. Transl Med. 6, 264ra165 (2014).
Bruckner-Tuderman, L., McGrath, J. A., Robinson, E. C. & Uitto, J. Animal models of epidermolysis bullosa: update 2010. J. Invest. Dermatol. 130, 1485–1488 (2010).
Uitto, J., Bruckner-Tuderman, L., McGrath, J. A., Riedl, R. & Robinson, C. EB2017 — progress in epidermolysis bullosa research toward treatment and cure. J. Invest. Dermatol. 138, 1010–1016 (2018).
Munger, J. S. et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319–328 (1999).
Hahm, K. et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am. J. Pathol. 170, 110–125 (2007).
Odorisio, T. et al. Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity. Hum. Mol. Genet. 23, 3907–3922 (2014). A case of monozygotic twins with severe recessive dystrophic EB with identical type VII collagen abnormalities but divergent phenotypes owing to differences in TGFβ signalling pathways.
Cianfarani, F. et al. Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa. Matrix Biol. 81, 3–16 (2019).
Järvinen, T. A. H. & Prince, S. Decorin: a growth factor antagonist for tumor growth inhibition. Biomed. Res. Int. 2015, 654765 (2015).
Reed, C. C., Gauldie, J. & Iozzo, R. V. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 3688–3695 (2002).
Nyström, A. et al. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol. Med. 7, 1211–1228 (2015).
Tolar, J. & Wagner, J. E. A biologic velcro patch. N. Engl. J. Med. 372, 382–384 (2015).
Twaroski, K. et al. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa. Br. J. Dermatol. 181, 1247–1253 (2019).
Ortiz-Urda, S. et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J. Clin. Invest. 111, 251–255 (2003).
Jacków, J. et al. Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a self-inactivating COL7A1 retroviral vector. J. Invest. Dermatol. 136, 1346–1354 (2016).
Siprashvili, Z. et al. Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes. J. Invest. Dermatol. 137, S89 (2017).
Woodley, D. T. et al. Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J. Invest. Dermatol. 133, 1910–1913 (2013). Intravenously administered recombinant type VII collagen in a mouse model restored type VII collagen, anchoring fibrils and dermal–epidermal adhesion.
Bornert, O. et al. RNA-based therapies for genodermatoses. Exp. Dermatol. 26, 3–10 (2017).
Bremer, J. et al. Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa. Mol. Ther. Nucleic Acids 5, e379 (2016).
Turczynski, S. et al. Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model. J. Invest. Dermatol. 136, 2387–2395 (2016).
Bremer, J. et al. Natural exon skipping sets the stage for exon skipping as therapy for dystrophic epidermolysis bullosa. Mol. Ther. Nucleic Acids 18, 465–475 (2019).
Kerns, M. L. et al. Randomized, split-body, single-blinded clinical trial of topical broccoli sprout extract: assessing the feasibility of its use in keratin-based disorders. J. Am. Acad. Dermatol. 76, 449–453.e1 (2017).
Wally, V. et al. Diacerein orphan drug development for epidermolysis bullosa simplex: a phase 2/3 randomized, placebo-controlled, double-blind clinical trial. J. Am. Acad. Dermatol. 78, 892–901.e7 (2018).
Tolar, J. et al. Montagna symposium 2017 — precision dermatology: next generation prevention, diagnosis, and treatment. J. Invest. Dermatol. 138, 1243–1248 (2018).
Tamai, K. et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group Box 1 (HMGB1) to regenerate injured epithelia. Proc. Natl Acad. Sci. USA 108, 6609–6614 (2011).
Aikawa, E., Fujita, R., Kikuchi, Y., Kaneda, Y. & Tamai, K. Systemic high-mobility group Box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFRα+ mesenchymal cells from bone marrow. Sci. Rep. 5, 11008 (2015).
March, O. P., Reichelt, J. & Koller, U. Gene editing for skin diseases: designer nucleases as tools for gene therapy of skin fragility disorders. Exp. Physiol. 103, 449–455 (2018).
Shipman, A. R., Liu, L., Lai-Cheong, J. E., McGrath, J. A. & Heagerty, A. Somatic forward (nonrevertant) mosaicism in recessive dystrophic epidermolysis bullosa. JAMA Dermatol. 150, 1025–1027 (2014).
Wright, J. T. Oral manifestations in the epidermolysis bullosa spectrum. Dermatol. Clin. 28, 159–164 (2010).
Wiebe, C. B. et al. Clinical and microbiologic study of periodontitis associated with Kindler syndrome. J. Periodontol. 74, 25–31 (2003).
Simmer, J. P. & Fincham, A. G. Molecular mechanisms of dental enamel formation. Crit. Rev. Oral. Biol. Med. 6, 84–108 (1995).
The authors declare no competing interests.
The authors affirm that human research participants provided informed consent for publication of the images in Fig. 3.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Mechanobullous disorder
A group of inherited disorders characterized by skin fragility and blister formation secondary to trauma.
A cutaneous change showing concurrent atrophy (thinning), telangiectasia (visible blood vessels), hypopigmentation and hyperpigmentation.
A structure at the lower surface of basal keratinocytes, extending from the intracellular compartment to the lamina lucida, with a critical role in adhesion and implicated in keratinocyte migration.
A specialized junctional complex in the lateral surface of plasma membranes enabling cell–cell adhesion.
The susceptibility of a substance to change (or destruction) in response to heat.
- Null mutations
Genetic mutations that result in a complete lack of functional protein product or no protein production at all.
Abnormal thickening of the stratum corneum, the outermost layer of the skin.
- Shave biopsy
A surgical procedure whereby a thin layer of skin is removed with a sharp blade for the purpose of microscopic examination.
- Germline mosaicism
Occurs when more than one set of genetic information is present in the gamete cells, arising owing to mutations that occur post-conception.
- Uniparental isodisomy
The inheritance of both copies of a chromosome, or part of a chromosome, from a single parent, with no copies received from the other parent.
- Chorionic villus sampling
Prenatal sampling of placental tissue during early pregnancy, undertaken via the cervix or through the abdomen to screen for chromosomal or genetic abnormalities in the developing fetus.
The sampling of amniotic fluid during pregnancy via insertion of a needle into the uterus to screen for abnormalities in the developing fetus.
- Oesophageal webs
Thin mucosal membrane webs that project into the oesophageal lumen causing constriction, making swallowing difficult.
A glycoprotein hormone secreted by the kidney in response to hypoxia to stimulate erythrocyte (red blood cell) production or erythropoiesis in the bone marrow.
Inflammation of the eyelid.
An abnormal growth of granulation or fibrovascular tissue.
Adhesion of the palpebral conjunctiva of the eyelid to the bulbar conjunctiva.
- Revertant mosaicism
Spontaneous abolition of pathogenetic mutations within somatic cells of an affected individual; in epidermolysis bullosa, this results in localized areas of unaffected skin due to expression of functional protein.
Adapted from a naturally occurring bacterial immune mechanism, CRISPR-associated protein 9 (Cas9) is an enzyme that uses clustered regularly interspaced short palindromic repeats (CRISPR) sequences as a guide to perform cleavage of specific DNA strands, enabling precise genome editing.
Colony-forming keratinocyte stem cells with the greatest replicative capacity in which <5% of the cells in a clone abort and undergo terminal differentiation.
Colony-forming keratinocytes with a mix of reproductive capacity between that of holoclones and paraclones.
Colony-forming keratinocytes characterized exclusively by cells of limited reproductive lifespans, not more than 15 generations, following which they abort and undergo terminal differentiation.
About this article
Cite this article
Bardhan, A., Bruckner-Tuderman, L., Chapple, I.L.C. et al. Epidermolysis bullosa. Nat Rev Dis Primers 6, 78 (2020). https://doi.org/10.1038/s41572-020-0210-0
This article is cited by
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex
Orphanet Journal of Rare Diseases (2022)
Journal of Medical Case Reports (2022)
Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa
Orphanet Journal of Rare Diseases (2022)
Multidisciplinary care for patients with epidermolysis bullosa from birth to adolescence: experience of one Italian reference center
Italian Journal of Pediatrics (2022)
Post-translational modifications to hemidesmosomes in human airway epithelial cells following diacetyl exposure
Scientific Reports (2022)